Williams Cancer Institute

Zinc acetate plus intratumoral immunotherapy for prostate cancer

When you’re doing intratumoral immunotherapy, there’s one aspect that really enhances the immune response. It’s what we call a lytic agent or a lytic process. This can be ablations. It can be cryoablation, pulse electrical field or other ablative technologies, or it can actually be an injectable agent itself. Chemotherapy, in some ways will function as a lytic agent. You get tumor killing. That gives us pieces of a dead tumor that the immune system can see, boosting that immune response. But interesting enough, in prostate cancer, it has been shown that zinc is actually toxic to prostate cancer cells. So, when you have a prostate cancer, that’s more infiltrative, so you don’t have afocal area you can target with ablation, but you’ve got scattered out tumor cells. You want to kill this cancer, get pieces, dead pieces. But you don’t want to kill normal tissue. Zinc acetate has been shown to do just that. And don’t take my word for it, look it up and you can see that zinc kills prostate cancer. There’s many things that you can inject into cancer to kill it. And when you combine it with immunotherapy, you get those dead pieces like an ablation. But with immunotherapy, it’s synergy.There’s many, many options. So certainly this can enhance abscopal effect, not only treating the local disease, but the advanced distant disease as well.

Reference: Maulik R Shah, Christopher L Kriedt, Nathan H Lents, Mary K Hoyer,  Nimah Jamaluddin,Claudette Klein, Joseph Baldassare, 2009 Jun 17, Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701928/

Related Posts

Blog 18 de Julio de 2024
Blog 16 de Julio de 2024
bLog 11 de Julio de 2024
1 2 3 108